Drug Approval | July 13, 2024
Lupin receives EIR from USFDA for its Dabhasa facility
The facility is a part of Lupin Manufacturing Solutions
The facility is a part of Lupin Manufacturing Solutions
Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Establishing Asymchem’s first manufacturing footprint in Europe
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry
Subscribe To Our Newsletter & Stay Updated
